Market Vectors MSCI Emerging Markets Quality ETF QEM 深 沪
等待开盘 10-20 09:30:00 美东时间
0.00
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 总市值 0
- 52周最高 0.00
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 0.00
- 委 比 0.00%
- 总股本 --
- 历史最高 0.00
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 0.00
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Eisai And Biogen Announce Lecanemab-Irmb Subcutaneous Injection Is Now Available In US As Maintenance Dosing Regimen For AD Treatment
New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an injection
10-07 04:34
Eisai And Biogen's LEQEMBI Approved By Australia's TGA For Early Alzheimer's In ApoEε4 Non-Carriers And Heterozygotes
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen"))) announced today that the
09-24 19:34
Leqembi® approved for the treatment of early Alzheimer's disease in Australia
STOCKHOLM, Sept. 24, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved lecanemab...
09-24 14:56
QEM Limited Reassesses Julia Creek Project Amid Challenging Test Results
QEM Limited ( ($AU:QEM) ) has shared an announcement. QEM Limited has announced...
09-23 15:17
卫材申请仑卡奈单抗IQLIK的滚动补充生物制品许可
卫材已启动向美国食品药品监督管理局（FDA）提交仑卡奈单抗（美国商品名：LEQEMBI，中文商品名：乐意保）皮下自动注射剂型（SC-AI）IQLIK作为每周起始...
09-05 13:45
Eisai Co. And Biogen Announce FDA Approval For LEQEMBI IQLIK Subcutaneous Injection For Maintenance Dosing For The Treatment of Early Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass., Aug. 29, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher
08-30 05:08
Biogen And Eisai Report LEQEMBI Slowed Alzheimer's Decline By 1.75 Points Over 4 Years, Preserved Function In 56% of Low-Tau Patients
Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer's Disease56% of Patients with Low Tau Continued to Demonstrate Improved Cognitive
07-30 20:09
Reported Earlier, Biogen To Present 48-Month LEQEMBI Clarity AD Data And Subcutaneous Dosing Insights At Alzheimer's Association International Conference 2025
Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued carePresentations on tau to explore its biological role, the development of
07-22 15:02
QEM Limited Announces Director Resignation and Securities Interests
QEM Limited ( ($AU:QEM) ) just unveiled an update. QEM Limited has announced th...
07-02 09:08
QEM Limited Announces Director’s Share Sale
QEM Limited ( ($AU:QEM) ) has issued an announcement. QEM Limited has announced...
06-25 11:17
